A phase III trial revealed that mepolizumab, a monoclonal antibody targeting interleukin-5, reduced exacerbation frequency in patients with chronic obstructive pulmonary disease (COPD) and elevated eosinophil levels. The study enrolled 804 participants and demonstrated a 21% relative reduction in exacerbation rate with mepolizumab compared to placebo, along with longer time to first exacerbation and fewer emergency visits or hospitalizations.

Source: The New England Journal of Medicine